Provider: Thomson Reuters Stock Report
4D Pharma PLC: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
4d Pharma PLC receives orphan drug designation for Rosburix
4d Pharma PLC:Says the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Rosburix, for the treatment of ulcerative colitis in paediatric patients (PUC).Rosburix is 4D's second live biotherapeutic to receive orphan designation, having received orphan designation from the FDA for the treatment of paediatric Crohns with Thetanix in Sept. 2013.
Latest Developments for 4D Pharma PLC
Latest Key Developments in Biotechnology
- Neurocrine Biosciences Inc receives breakthrough therapy designation for NBI-98854 in Tardive Dyskinesia
- Acorda Therapeutics Inc raises FY 2014 AMPYRA net revenue outlook
- Quintiles Transnational Holdings Inc raises FY 2014 EPS guidance
- Chiome Bioscience Inc amends consolidated full-year outlook for FY 2014
- Share this
- Digg this